First National Advisers LLC Has $7.99 Million Stake in Abbott Laboratories (NYSE:ABT)

First National Advisers LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,601 shares of the healthcare product maker’s stock after selling 151 shares during the quarter. Abbott Laboratories comprises approximately 1.3% of First National Advisers LLC’s investment portfolio, making the stock its 12th biggest holding. First National Advisers LLC’s holdings in Abbott Laboratories were worth $7,985,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Noble Wealth Management PBC bought a new position in Abbott Laboratories during the 4th quarter worth approximately $26,000. NewSquare Capital LLC boosted its stake in Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock worth $27,000 after acquiring an additional 105 shares during the last quarter. Rialto Wealth Management LLC bought a new position in Abbott Laboratories during the 4th quarter worth approximately $29,000. Peterson Financial Group Inc. bought a new position in Abbott Laboratories during the 3rd quarter worth approximately $32,000. Finally, Wingate Wealth Advisors Inc. bought a new position in Abbott Laboratories in the fourth quarter valued at approximately $34,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT opened at $127.02 on Friday. The company has a market cap of $220.29 billion, a price-to-earnings ratio of 16.60, a PEG ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23. The company’s fifty day simple moving average is $127.16 and its 200 day simple moving average is $119.43. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. During the same period in the previous year, the company earned $1.19 earnings per share. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. On average, research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.86%. Abbott Laboratories’s dividend payout ratio is currently 30.85%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 562 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the transaction, the senior vice president now directly owns 31,970 shares in the company, valued at $4,417,294.90. The trade was a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the completion of the transaction, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. This trade represents a 15.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 116,449 shares of company stock worth $15,463,316 over the last ninety days. Insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ABT shares. UBS Group lifted their price target on shares of Abbott Laboratories from $146.00 to $148.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Evercore ISI lifted their price target on shares of Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research note on Thursday, January 2nd. The Goldman Sachs Group lifted their price target on shares of Abbott Laboratories from $138.00 to $154.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Wells Fargo & Company lifted their price target on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, January 23rd. Finally, Barclays reaffirmed an “overweight” rating and issued a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $137.94.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.